Navigation Links
Braeburn Pharmaceuticals and Camurus announces start of Phase 3 trial of long-acting buprenorphine treatments for opioid dependence
Date:12/15/2015

PRINCETON, N.J. and LUND, Sweden, Dec. 15, 2015 /PRNewswire/ -- Braeburn Pharmaceuticals and Camurus today announced that the first patient has been enrolled in a Phase 3 clinical trial of CAM2038, long-acting subcutaneous buprenorphine injections for treatment of opioid dependence. The Phase 3 trial is designed to demonstrate the long-term safety and clinical efficacy of CAM2038 weekly and monthly injections in patients with opioid dependence. The study is a part of the pivotal registration program for CAM2038 for which Braeburn and Camurus have received guidance from both US Food and Drug Administration (FDA) and the European Medical Agency (EMA).

"Patients with opioid dependence need and deserve new treatment options. Our vision is to bring a suite of individualized long-acting treatments to patients struggling with opioid dependence as quickly as possible," said Behshad Sheldon, President and CEO of Braeburn Pharmaceuticals. "The beginning of this Phase 3 trial with the CAM2038 formulations is another important step in our efforts to contain and diminish the negative impacts of opioid addiction."

The Phase 3 study is an open-label international, multi-center, 12-month (48-week) safety trial assessing CAM2038 Once Weekly (q1w) and Once Monthly (q4w) in patients with opioid use disorder. The study includes both new entrants who are actively seeking treatment, and patients currently receiving maintenance treatment with sublingual buprenorphine. New entrants to treatment are initiated with the CAM2038 weekly product. Dose adjustments and switching between the weekly and monthly products is allowed during the study.

"Participation in this study represents an opportunity to assist in the development of novel ways of administering treatment for opioid dependence," said Dr. Jakob Billeskov Jansen, M.D., Center for Addiction Treatment, Aarhus, Denmark. "The CAM2038 long-acting injections may solve several difficulties relating to currently available daily medications and may ultimately become an important tool for helping patients in the management of their condition towards long-term recovery"

"Starting enrollment of patients in this global Phase 3 trial represents a key milestone in the development of our long-acting buprenorphine products. Along with the recently started Phase 2 opioid blockade study and a second Phase 3 trial under initiation, it forms the basis for forthcoming regulatory submissions," said Fredrik Tiberg, President and CEO, Camurus. 

About Braeburn Pharmaceuticals
Braeburn Pharmaceuticals, an Apple Tree Partners company, is a pill-free pharmaceutical company delivering precision medicine in neuroscience. In September 2015 the Food and Drug Administration (FDA) accepted for review Braeburn's New Drug Application for its lead candidate, Probuphine®, a six-month buprenorphine implant for treatment of opioid addiction. The Agency set February 27, 2016 as the target date for action.

Long-acting therapeutic treatment options can be essential to improving patient outcomes and facilitating recovery in these conditions, which are often complicated by stigma and present significant public health challenges. Braeburn's investigational product pipeline consists of long-acting implantable and injectable therapies for serious neurological and psychiatric disorders, including opioid addiction, pain, and schizophrenia. Candidates include: Probuphine®, a six-month buprenorphine implant for treatment of opioid addiction; CAM2038, weekly and monthly subcutaneous injection depot formulations of buprenorphine for treatment of opioid addiction and pain; a risperidone six-month implant for treatment of schizophrenia; and a novel molecule, ATI-9242, for treatment of schizophrenia. More information on Braeburn, can be found at www.braeburnpharma.com.  

About CAM2038
The investigational CAM2038 buprenorphine subcutaneous injection products for treatment of opioid addiction are being developed as once-weekly and once-monthly formulations, each with multiple doses, to cover all phases of treatment from initiation through maintenance.  The CAM2038 products are designed for administration by healthcare personnel to ensure proper delivery that minimizes the risks of diversion, abuse, misuse, and accidental exposure. The CAM2038 products have been evaluated in three Phase 1/2 clinical trials, which evaluated the safety and tolerability as well as pharmacokinetic and pharmacodynamic properties of the products in a total of 176 individuals (opioid-dependent patients and healthy volunteers under naltrexone blockage).

About Camurus
Camurus is a Swedish research-based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the proprietary FluidCrystal® drug delivery technologies and an extensive R&D expertise. Camurus' clinical pipeline includes products for treatment of cancer, endocrine diseases, pain and addiction, developed in-house and in collaboration with international pharmaceutical companies. The company's share is listed on Nasdaq Stockholm under the ticker "CAMX". For more information, visit www.camurus.com.

Media contacts:
Fredrik Tiberg, President & CEO
Tel: +46 (0)46 286 46 92
ir@camurus.com

Sherry Feldberg
MSLGROUP Boston
781-684-0770
braeburnpharma@mslgroup.com

Logo - http://photos.prnewswire.com/prnh/20150607/221301LOGO

Logo - http://photos.prnewswire.com/prnh/20151104/283936LOGO


'/>"/>
SOURCE Braeburn Pharmaceuticals; Camurus
Copyright©2015 PR Newswire.
All rights reserved


Related medicine technology :

1. Braeburn Pharmaceuticals And Titan Pharmaceuticals Announce Date Of FDA Advisory Committee Review Of Probuphine For Opioid Addiction
2. Dr. Frank Young of Braeburn Pharmaceuticals Receives 2015 Distinguished Scientist Award from American College of Toxicology
3. Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments
4. Validus Pharmaceuticals Further Expands Marketed U.S. Portfolio with Product Lines Purchased from Leading Healthcare Company
5. AcelRx Pharmaceuticals Conducts Pre-NDA Meeting with U.S. Food and Drug Administration for ARX-04
6. RXi Pharmaceuticals to Present at the 8th Annual Biotech Showcase 2016
7. Imprimis Pharmaceuticals Reports Results of Independent Third Party Potency Analysis of its Compounded Pyrimethamine and Leucovorin Capsules
8. Isis Pharmaceuticals Announces Initiation of Phase 1/2 Clinical Study of ISIS-SOD1 Rx in Patients With ALS
9. PharmaBoardroom Releases New Romania Pharmaceuticals Report
10. Rock Creek Pharmaceuticals to Present at Biotech Showcase 2016
11. Kitov Pharmaceuticals to Announce Interim Results of the Pivotal Phase III Trial on December 15, 2015 at 7:00am ET
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2019)... (PRWEB) , ... September 22, 2019 , ... ... Bellevue, WA offering the highest level of both plastic surgery and non-surgical aesthetic ... FDA-cleared microneedling device. Microneedling is a proven skin rejuvenation treatment that uses tiny ...
(Date:9/18/2019)... WASHINGTON, Pa. (PRWEB) , ... ... ... Inc. (USH), parent organization to ReachMD, Global Learning Collaborative, and other healthcare-focused ... digital learning environment, DecisionSimâ„¢, uses real-world cases to challenge healthcare professionals (HCPs) ...
(Date:9/17/2019)... (PRWEB) , ... September 18, 2019 , ... Uniform ... Beyond Breast Cancer to raise funds for Breast Cancer programs and services. , This ... 42,000 will die of the disease. During the month of October 2019, Uniform Advantage ...
Breaking Medicine Technology:
(Date:9/18/2019)... ... , ... A new study by BestPlaces looks at ten indicators to produce the first ranking ... so other related rights vary widely across the 50 states. , Ten topics ... orientation) , Employment , Education , Gender Marker Updates ...
(Date:9/17/2019)... ... 17, 2019 , ... Since the registration of the NociScan ... in the US, Nocimed has been marketing its unique technology to healthcare clinicians ... MRI equipment to perform MR spectroscopy, NociScan detects the presence of chemical biomarkers ...
(Date:9/17/2019)... N.Y. (PRWEB) , ... September 17, 2019 , ... ... medicine cabinet could help extend the lives of some cancer patients? In companion ... Chicago, doctors from Roswell Park Comprehensive Cancer Center report new evidence that low-dose ...
(Date:9/17/2019)... ... 17, 2019 , ... The Center for Information and Study ... third edition of The Gift of Participation. Written by CISCRP Founder, Ken Getz, ... navigate the clinical research process. The new edition offers a fresh look at ...
(Date:9/12/2019)... (PRWEB) , ... September 12, 2019 , ... ... both a local and national scale in two recent and well-renowned listing publications, ... fastest-growing privately held businesses for the 2019 year. , Dr. Jeffrey Donaldson, ...
Breaking Medicine News(10 mins):